Endometrial cancer — cancer of the uterine lining — is the most common gynecologic cancer in developed countries and is rising in incidence, partly linked to increasing obesity rates. Most cases are caught early when surgery is curative, but advanced or recurrent disease has historically had limited options.
What's actually going on in research
Checkpoint immunotherapy has become a cornerstone for mismatch repair-deficient (MSI-H/dMMR) endometrial cancers, and pembrolizumab-based combinations have improved outcomes broadly across molecular subtypes. Antibody-drug conjugates targeting HER2 and other surface proteins are showing strong activity in specific subtypes. Molecular classification — into POLE-mutated, dMMR, copy-number-low, and copy-number-high groups — now guides treatment decisions and is a major focus of ongoing trials.
Checkpoint immunotherapy
PD-1 inhibitors are now combined with chemotherapy as standard therapy for advanced endometrial cancer, with particularly strong responses in dMMR tumors. Trials are testing them in earlier-stage disease.
Antibody-drug conjugates
Drugs targeting HER2, folate receptor alpha, and other proteins overexpressed in endometrial cancer are in active trials, offering options for platinum-resistant and recurrent disease.
Molecular subtype treatment
Trials are prospectively testing whether POLE-mutated and other specific subtype patients can safely de-escalate treatment, and whether FGFR3-targeted drugs benefit the copy-number-high group.
What to know before you search
Eligibility depends on stage, molecular subtype (POLE, dMMR, FGFR3), HER2 status, and prior platinum-based chemotherapy.
What types of trials are currently open
- Treatment trials — Testing new drug combinations or immunotherapy for advanced, recurrent, or metastatic endometrial cancer.
- Adjuvant trials — Testing post-surgery chemotherapy, radiation, or immunotherapy for high-risk early-stage disease.
- Molecular subtype trials — Testing de-escalation or targeted therapy based on molecular classification.
- Surgical trials — Comparing minimally invasive surgical approaches and sentinel lymph node biopsy techniques.
- Supportive care trials — Managing sexual function, lymphedema, and other treatment effects.
Recently added Endometrial Cancer trials
Fasting InTervention for Endometrial Cancer
The goal of this study is to find out if it is safe for women with endometrial cancer who are going to have surgery to fast (not eat) overnight. Studies have shown that women with endometrial cancer often have problems with metabolism, like high blood sugar. These problems can cause inflammation and may help cancer grow or make treatment less effective. Early research shows that fasting overnight might help improve these problems.
Take an experimental cancer drug to test safety and effectiveness
This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-6452 in adult patients with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) advanced/metastatic breast cancer or locally advanced/metastatic solid tumor.
Find Endometrial Cancer trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.